Bessemer Group
TVTX icon

Bessemer Group’s Travere Therapeutics TVTX Stock Holding History

Bessemer Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5K Sell
155
-51
-25% -$1.52K ﹤0.01% 2242
2025
Q4 		$8K Sell
206
-96
-32% -$3.12K ﹤0.01% 2172
2025
Q3 		$7K Buy
302
+96
+47% +$1.8K ﹤0.01% 2073
2025
Q2 		$3K Hold
206
– – ﹤0.01% 2159
2025
Q1 		$4K Buy
206
+41
+25% +$832 ﹤0.01% 2117
2024
Q4 		$3K Hold
165
– – ﹤0.01% 2164
2024
Q3 		$2K Sell
165
-169
-51% -$1.76K ﹤0.01% 2283
2024
Q2 		$3K Buy
+334
New +$2.25K ﹤0.01% 1902
2022
Q2 		– Sell
-221
Closed -$6K – 2030
2022
Q1 		$6K Hold
221
– – ﹤0.01% 1487
2021
Q4 		$7K Hold
221
– – ﹤0.01% 1511
2021
Q3 		$5K Hold
221
– – ﹤0.01% 1522
2021
Q2 		$3K Hold
221
– – ﹤0.01% 1496
2021
Q1 		$6K Buy
+221
New +$6.11K ﹤0.01% 1381
2020
Q3 		– Sell
-99,800
Closed -$2.04M – 1659
2020
Q2 		$2.04M Buy
+99,800
New +$1.59M 0.01% 473
2019
Q4 		– Sell
-66
Closed -$1K – 1763
2019
Q3 		$1K Buy
+66
New +$1.09K ﹤0.01% 1686

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bessemer Group's TVTX Position: Q1 2026 in Review

Bessemer Group reduced its Travere Therapeutics (TVTX) stake by 25% in Q1 2026, selling an estimated $1.52K and leaving 155 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #2242.

Bessemer Group first reported a position in TVTX in Q3 2019 and has held it in 15 quarters since. The position peaked at $2.04M in Q2 2020. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Bessemer Group held 155 shares of Travere Therapeutics worth $5K as of Q1 2026.
  • Bessemer Group sold 51 Travere Therapeutics shares in Q1 2026, an estimated $1.52K.
  • Travere Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #2242 holding.
  • Bessemer Group first reported a position in Travere Therapeutics in Q3 2019 and has held it in 15 quarters since.
  • Bessemer Group's Travere Therapeutics position peaked at $2.04M in Q2 2020.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.